

**Strides Pharma Science Pty Ltd**  
**Balance Sheet As At March 31, 2024**

	Note No.	Amount in AUD	
		31-Mar-24	31-Mar-23
<b>A ASSETS</b>			
<b>I Non-current assets</b>			
(a) Other intangible assets		443,003	524,772
<b>Total non-current assets</b>		<b>443,003</b>	<b>524,772</b>
<b>II Current assets</b>			
(a) Financial assets			
(i) Trade receivables	1	17,087	
(i) Cash and cash equivalents	2	6,277	6,963
(b) Other Current Assets	3	312,115	248,987
<b>Total current assets</b>		<b>335,479</b>	<b>255,950</b>
<b>TOTAL ASSETS</b>		<b>778,482</b>	<b>780,722</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	4	2,640,836	2,547,082
(b) Reserves and Surplus	5	(1,877,510)	(1,781,204)
<b>Total Equity</b>		<b>763,326</b>	<b>765,878</b>
<b>II Liabilities</b>			
<b>1 Current liabilities</b>			
(a) Financial liabilities			
(i) Trade payables	6	9,004	8,845
(b) Other current liabilities	7	6,153	5,999
<b>Total current liabilities</b>		<b>15,157</b>	<b>14,844</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>778,482</b>	<b>780,722</b>

**Strides Pharma Science Pty Ltd**  
**Statement Of Profit And Loss For The Year Ended March 31, 2024**

Particulars	Note No.	Amount in AUD	
		31-Mar-24	31-Mar-23
1 Revenue from operations		-	
2 Other Income		-	
<b>3 Total Revenue (1+2)</b>		-	-
<b>4 Expenses</b>			
(a) Cost of material consumed		-	
(b) Employee benefits expense	8	136,598	135,982
(c) Finance costs	9	213	279
(d) Depreciation and amortisation expense		81,769	82,366
(e) Other expenses	10	234,431	103,560
<b>Total expenses</b>		<b>453,011</b>	<b>322,187</b>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>(453,011)</b>	<b>(322,187)</b>
6 Exceptional Item		-	-
<b>7 Profit / (Loss) before taxes (5+6)</b>		<b>(453,011)</b>	<b>(322,187)</b>
<b>8 Tax Expense:</b>			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
<b>9 Profit / (Loss) for the year after tax</b>		<b>(453,011)</b>	<b>(322,187)</b>

**STRIDES PHARMA SCIENCE PTY LTD  
STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED MARCH 31, 2024**

**(A) Equity share capital**

Particulars	Amount in AUD
Balance as at March 31,2023	2,547,082
Changes in equity share capital during the year	93,754
<b>Balance as at March 31,2024</b>	<b>2,640,836</b>

**(B) Other equity**

Amount in AUD

Particulars	Money pending allotment	Reserves and Surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31,2023	(334,773)	(1,446,431)	-	(1,781,204)
Profit/loss for the year	-	(453,011)	-	(453,011)
Movement during the year	356,705	-	-	356,705
<b>Total comprehensive income</b>	<b>21,932</b>	<b>(1,899,442)</b>	<b>-</b>	<b>(1,877,510)</b>
<b>Balance as at March 31, 2024</b>	<b>21,932</b>	<b>(1,899,442)</b>	<b>-</b>	<b>(1,877,510)</b>

Strides Pharma Science Pty Ltd  
Notes forming part of financial statement

Note No.

1 Trade receivables		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
<b>Unsecured</b>			
Considered good	17,087		
Considered doubtful			
	17,087		-
Less: Allowance for doubtful trade receivables			
<b>Total</b>	<b>17,087</b>		<b>-</b>

2 Cash and cash equivalents		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
Balances with banks:			
In current accounts	6,277		6,963
<b>Total</b>	<b>6,277</b>		<b>6,963</b>

3 Other current assets		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
<b>Unsecured, considered good</b>			
Receivable from related parties	76,249		84,004
Advances to others	221,890		154,236
Balances with government authorities:			
- GST receivable	667		1,062
Prepaid expenses	13,309		9,684
<b>Total</b>	<b>312,115</b>		<b>248,987</b>

4 Share capital		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
Issued, subscribed and fully paid-up Equity share capital	2,640,836		2,547,082
<b>Total</b>	<b>2,640,836</b>		<b>2,547,082</b>

5 Reserves and surplus		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
Share Application money Pending Allotment	21,932		369,757
Add: Addition during the year			(704,530)
<b>Share Application money Pending Allotment</b>	<b>21,932</b>		<b>(334,773)</b>
<b>Surplus in statement of profit and loss</b>			
Opening balance	(1,446,431)		(1,124,244)
Add: Profit / (Loss) for the year	(453,011)		(322,187)
<b>Closing balance</b>	<b>(1,899,442)</b>		<b>(1,446,431)</b>
<b>Total</b>	<b>(1,877,510)</b>		<b>(1,781,204)</b>

6 Trade payables		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
Trade payable	9,004		8,845
<b>Total</b>	<b>9,004</b>		<b>8,845</b>

7 Other current liabilities		Amount in AUD	
Particulars	31-Mar-24	31-Mar-23	
Others	6,153		5,999
<b>Total</b>	<b>6,153</b>		<b>5,999</b>

**Strides Pharma Science Pty Ltd**  
**Notes forming part of financial statement**

**8 Employee benefit expenses** **Amount in AUD**

Particulars	31-Mar-24	31-Mar-23
Salaries and wages	136,598	135,982
<b>Total</b>	<b>136,598</b>	<b>135,982</b>

**9 Finance cost** **Amount in AUD**

Particulars	31-Mar-24	31-Mar-23
Bank charges	213	279
<b>Total</b>	<b>213</b>	<b>279</b>

**10 Other expenses** **Amount in AUD**

Particulars	31-Mar-24	31-Mar-23
Power and fuel	642	405
Rent	-	3,094
Rates & taxes	192,909	34,204
Courier Charges	52	127
Insurance	1,295	1,096
Conveyance & travelling	133	-
Advertisement & Selling expenses	-	877
Membership fees and subscription	5,349	6,609
Sundry balance of written back	3	-
Net loss on foreign currency transactions	8,099	32,761
Professional fees & Legal fees	25,949	24,387
<b>Total</b>	<b>234,431</b>	<b>103,560</b>